GlucoTrack, Inc. (GCTK)
NASDAQ: GCTK · Real-Time Price · USD
0.8370
+0.1140 (15.77%)
At close: Apr 28, 2026, 4:00 PM EDT
1.060
+0.223 (26.64%)
Pre-market: Apr 29, 2026, 5:21 AM EDT
GlucoTrack Earnings Call Transcripts
Fiscal Year 2026
-
Three key proposals were presented: share issuances to an investor, warrant exercise approval, and auditor ratification. All proposals received the required stockholder approval, with final results to be filed with the SEC.
Fiscal Year 2025
-
A reconvened special meeting aimed to approve a major stock issuance but was permanently adjourned due to lack of quorum, with only 17.6% of eligible votes represented.
-
A fully implantable, three-year continuous blood glucose monitor is being developed, targeting a 3 million patient U.S. market segment underserved by current wearables. Clinical trials are underway in Australia and planned for the U.S., with commercial approval aimed for late 2028.